Wenliang Tan^*†1, Sicong Zhu^*†1, Jun Cao^*†, Lei Zhang^*†, Wenda Li^*†, Kairui Liu^*†, Jinyi Zhong^†, Changzhen Shang^*†, Yajin Chen^*†

Oncology Research, Vol.25, No.9, pp. 1543-1553, 2017, DOI:10.3727/096504017X14886444100783

Abstract Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib is necessary to improve the antitumor efficiency. Here we demonstrated that expression of MMP-2 is positively correlated with the migration ability of HCC cells. Cells with a higher MMP-2 expression (SK-HEP-1 cells) were less sensitive to sorafenib than those with lower MMP-2 expression (HepG2 cells). Cotreatment of cells with SB-3CT and sorafenib more strongly inhibited… More >

Antonello Di Paolo¹, Paola Orlandi¹, Teresa Di Desidero, Romano Danesi, Guido Bocci

Oncology Research, Vol.25, No.7, pp. 1129-1140, 2017, DOI:10.3727/096504017X14841698396900

Abstract The combination of folinate salts to 5-fluoruracil (5-FU)-based schedules is an established clinical routine in the landscape of colorectal cancer treatment. The aim of this study was to investigate the pharmacological differences between the sequential administration of folinate salts (1 h before, as in clinical routine) followed by 5-FU and the simultaneous administration of both drugs. Proliferation and apoptotic assays were performed on human colon cancer cells exposed to 5-FU, calcium (CaLV), or disodium (NaLV) levofolinate or their simultaneous and sequential combination for 24 and 72 h. TYMS and SLC19A1 gene expression was performed with… More >

Bingqian Ding¹, Bei Cui¹, Ming Gao, Zhenjiang Li, Chenyang Xu, Shaokang Fan, Weiya He

Oncology Research, Vol.25, No.3, pp. 331-340, 2017, DOI:10.3727/096504016X14736286083065

Abstract Ras-related protein 25 (Rab25) is a member of the Rab family, and it has been reported to play an important role in tumorigenesis. However, its direct involvement in human glioblastoma multiforme (GBM) is still unclear. The aim of the current study was to investigate the potential role of Rab25 in the growth, proliferation, invasion, and migration of human GBM. Our results showed that Rab25 expression was significantly higher in human GBM cell lines compared with a normal astrocyte cell line. In vitro functional studies revealed that knockdown of Rab25 reduced cell proliferation and inhibited invasion More >

Arya Sobhakumari^*1, Kevin P. Orcutt^†‡1, Laurie Love-Homan^§, Christopher E. Kowalski^†‡, Arlene D. Parsons^†, C. Michael Knudson^†‡§¶, Andrean L. Simons^*†‡§¶

Oncology Research, Vol.24, No.1, pp. 55-64, 2016, DOI:10.3727/096504016X14586627440192

Abstract Poor tumor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a significant challenge for effective treatment of head and neck squamous cell carcinoma (HNSCC). Therefore, strategies that may increase tumor response to EGFR TKIs are warranted in order to improve HNSCC patient treatment and overall survival. HNSCC tumors are highly glycolytic, and increased EGFR signaling has been found to promote glucose metabolism through various mechanisms. We have previously shown that inhibition of glycolysis with 2-deoxy-d-glucose (2DG) significantly enhanced the antitumor effects of cisplatin and radiation, which are commonly used to treat… More >

LING MA^1,#, ZIRUI JIANG^1,#, XIAO HOU¹, YUTING XU¹, ZIYUN CHEN¹, SIYI ZHANG¹, HANXUE LI¹, SHAOJIE MA¹, GENG ZHANG², XIUJUN WANG^1,*, JING JI^1,*

BIOCELL, Vol.48, No.5, pp. 847-860, 2024, DOI:10.32604/biocell.2024.050868

Abstract Background: Regulatory proteins involved in human cellular division and proliferation, cyclin-dependent kinases 4 and 6 (CDK4/6) are overexpressed in numerous cancers, including triple-negative breast cancer (TNBC). TNBC is a common pathological subtype of breast cancer that is prone to recurrence and metastasis, and has a single treatment method. As one of the CDK4/6 inhibitors, abemaciclib can effectively inhibit the growth of breast tumors. In this study, we synthesized LA-D-B1, a derivative of Abemaciclib, and investigated its anti-tumor effects in breast cancer. Methods: Cellular viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell cloning and… More >

JINGJING CHEN¹, DAN WANG², ZEQUN WANG², MENGYUAN HAN⁴, HOUQING YIN², WENTING ZHOU⁴, RIBAI YAN⁵, YAN PAN^2,3,*

Oncology Research, Vol.32, No.5, pp. 911-923, 2024, DOI:10.32604/or.2023.042384

Abstract Photodynamic therapy (PDT) is a promising cancer treatment. This study investigated the antitumor effects and mechanisms of a novel photosensitizer meso-5-[ρ-diethylene triamine pentaacetic acid-aminophenyl]−10,15,20-triphenyl-porphyrin (DTP) mediated PDT (DTP-PDT). Cell viability, reactive oxygen species (ROS), and apoptosis were measured with a Cell Counting Kit-8 assay, DCFH-DA fluorescent probe, and Hoechst staining, respectively. Cell apoptosis- and autophagy-related proteins were examined using western blotting. RNA sequencing was used to screen differentially expressed mRNAs (DERs), and bioinformatic analysis was performed to identify the major biological events after DTP-PDT. Our results show that DTP-PDT inhibited cell growth and induced ROS… More > Graphic Abstract

FRANCESCO PETRELLA^*, ENRICO MARIO CASSINA, LIDIA LIBRETTI, EMANUELE PIRONDINI, FEDERICO RAVEGLIA, ANTONIO TUORO

Oncology Research, Vol.32, No.3, pp. 433-437, 2024, DOI:10.32604/or.2023.046497

Abstract The main aim of antineoplastic treatment is to maximize patient benefit by augmenting the drug accumulation within affected organs and tissues, thus incrementing drug effects and, at the same time, reducing the damage of non-involved tissues to cytotoxic agents. Mesenchymal stromal cells (MSC) represent a group of undifferentiated multipotent cells presenting wide self-renewal features and the capacity to differentiate into an assortment of mesenchymal family cells. During the last year, they have been proposed as natural carriers for the selective release of antitumor drugs to malignant cells, thus optimizing cytotoxic action on cancer cells, while More >

A. Rault, J. Terrasson, A. Brédart, S. Dolbeault

Psycho-Oncologie, Vol.17, No.2, pp. 79-84, 2023, DOI:10.3166/pson-2022-0213

Abstract Cet article rend compte des divers questionnements cliniques et éthiques apparus au cours de notre recherche en psycho-oncologie. Celle-ci porte sur la communication entre les oncologues et leurs patients, et les pédiatres-oncologues et les parents d’enfants malades à un moment particulier de la prise en charge : l’annonce de la résistance au traitement antitumoral et l’absence d’alternative curative connue. La mise en place d’une telle étude nécessite de prendre en compte les aspects émotionnels et psychologiques en jeu. Dans un premier temps, nous pré- sentons les interrogations portant sur le recrutement des participants : comment More >

LETIAN JIN, HETING CHEN, QI RUAN, RUI LIU, YIFENG FAN, XIUFANG XU, DAJIANG WANG^*, JIAHUI LU^*

BIOCELL, Vol.47, No.7, pp. 1483-1498, 2023, DOI:10.32604/biocell.2023.028457

Abstract During the chemotherapy of tumors, the cytotoxic effect of drugs is vital to kill tumor cells, and the delivery of a chemotherapeutic agent is of great importance for optimal therapeutic effects. The high in vivo clearance rate and low delivery efficiency of conventional chemotherapeutic agents affect the therapeutic effect. In recent years, the responsive drug delivery nanosystem has received increasing concern owing to its excellent biocompatibility, stable delivery performance, and controlled drug release strategies. To lucidly explain the cytocidal and immunotherapeutic effects of such responsive nanosystems in breast cancer, this review discusses the various stimuli and More >

Jie Wei^*†1, Yuanliang Yan^*†1, Xi Chen^*†, Long Qian^*†, Shuangshuang Zeng^*†, Zhi Li^‡, Shuang Dai^*†, Zhicheng Gong^*†,Zhijie Xu^§

Oncology Research, Vol.27, No.7, pp. 849-858, 2019, DOI:10.3727/096504018X15447833065047

Abstract Over the past decade, natural compounds have been proven to be effective against many human diseases, including cancers. Triptolide (TPL), a diterpenoid triepoxide from the Chinese herb Tripterygium wilfordii Hook F, has exhibited attractive cytotoxic activity on several cancer cells. An increasing number of studies have emphasized the antitumor effects of TPL on non-small cell lung cancer (NSCLC). Here we mainly focused on the key molecular signaling pathways that lead to the inhibitory effects of TPL on human NSCLC, such as mitogen-activated protein kinases (MAPKs) modulation, inhibition of NF- B activation, suppression of miRNA expression, More >